Abstract: A terminated hollow-core optical fiber includes an outer capillary having an end-face, a hollow-core optical fiber having a fiber-end located inside the outer capillary a non-zero distance away from the end-face of the outer capillary, a fiber jacket disposed on a surface of the hollow-core optical fiber, and an inner capillary disposed between the fiber jacket and an inner surface of the outer capillary. The inner capillary holds the hollow-core optical fiber via the fiber jacket such that the fiber-end protrudes from the inner capillary and is suspended inside the outer capillary. The terminated hollow-core optical fiber further includes an endcap adjacent the end-face of the outer capillary. This configuration positions the sensitive and potentially fragile fiber-end close to the endcap in a protected environment, while avoiding direct contact between the fiber-end and other mechanical structures, and can be realized without fusing anything to the light-transmitting surfaces of the endcap.

Abstract: The invention relates to the use of sirtuin inhibitors for reducing TNF-alpha production by cells and organisms. The invention also concerns prophylactic and therapeutic applications of sirtuin inhibitors in TNF-alpha mediated pathologies, such as various inflammatory and autoimmune disorders.

Abstract: The present invention relates to the use of an inhibitor of the formation of nicotinamide adenyl dinucleotide for the preparation of a medicament used in the treatment of inflammatory diseases such as rheumatoid arthritis and endotoxemia.